Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy

NCT04756037 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1164

Enrollment

INDUSTRY

Sponsor class

Conditions

Contraception

Interventions

DRUG: Relugolix Combination Therapy

Sponsor

Sumitomo Pharma Switzerland GmbH